Caliway Biopharmaceuticals, a clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics, announced two major clinical mi...
Eisai Co., Ltd. and Biogen Inc., announced that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in th...
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Au...
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML Innovent Biologics, Inc. (01801.HK) and ...
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical T...
CellFiber Co., Ltd. (“CellFiber”), a Tokyo-based biotechnology company built on its proprietary CellFiber® cell encapsulation platform, a...
Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized estimated eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/...
Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) dr...
Ember LifeSciences, Inc. ("Ember"), an award-winning provider of advanced pharmaceutical cold chain solutions, has entered into a capital and business al...
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...
Reached a long-term business cooperation with a large pharmaceutical company to help it promote production licensing and commercial supervision and app...
Anivive converts Laverdia-CA1 to full FDA approval First FDA-approved product to validate Anivive's AI-enabled development model — from drug rep...
First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch ex...
Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval ...
© 2026 Biopharma Boardroom. All Rights Reserved.
